Publisher
Springer Science and Business Media LLC
Reference65 articles.
1. Food and Drug Administration. Guidance for industry—immunogenicity assessment for therapeutic protein products, FDA, CDER/CBER; 2014.
2. European Medicines Agency. Guideline on immunogenicity assessment of therapeutic proteins (EMEA/CHMP/BMWP/14327/2006 Rev 1). Committee for Medicinal Products for Human Use (CHMP); 2017. Retrieved from http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/06/WC500228861.pdf. Accessed 12 Oct 2019.
3. Tangri S, Mothé BR, Eisenbraun J, Sidney J, Southwood S, Briggs K, et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol. 2005;174(6):3187–96. https://doi.org/10.4049/jimmunol.174.6.3187.
4. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol. 2007;28(11):482–90. https://doi.org/10.1016/j.it.2007.07.011.
5. Weber CA, Mehta PJ, Ardito M, Moise L, Martin B, De Groot AS. T cell epitope: friend or foe? Immunogenicity of biologics in context. Adv Drug Deliv Rev. 2009;61(11):965–76. https://doi.org/10.1016/j.addr.2009.07.001.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献